Product Description
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US paediatric, patients (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15733015/)
Mechanisms of Action: VDR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hyperparathyroidism | Hyperparathyroidism, Secondary | Kidney Diseases
Known Adverse Events: Edema
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Puerto Rico, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Hyperparathyroidism, Secondary|Kidney Diseases|Kidney Failure, Chronic
Phase 2: Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| M11-617 | P3 |
Recruiting |
Hyperparathyroidism, Secondary|Kidney Failure, Chronic |
2026-06-30 |
49% |
| NCT03520790 | P2 |
Active, not recruiting |
Pancreatic Cancer |
2024-08-01 |
|
| NABPLAGEMD | P2 |
Completed |
Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma |
2023-12-11 |
|
| NAPPCG-EB 2015-001 | P2 |
Completed |
Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer |
2023-04-11 |